DCGI gives EUA for mRNA-based Omicron-specific booster vaccine from Gennova


Active member

Gennova Biopharmaceuticals announced that its mRNA COVID-19 booster vaccine – GEMCOVAC-OM – against the Omicron variant of SARS-CoV-2 received emergency use authorisation (EUA) from the office of the Drugs Controller General of India (DCGI).

GEMCOVAC-OM is the first booster COVID-19 vaccine developed in India against the Omicron variant. Reportedly, GEMCOVAC-OM has demonstrated robust immune responses in the phase 3 clinical trial conducted at 20 centers across 13 cities in India In Phase-II/ III trials, approximately 3000 individuals received GEMCOVAC-OM and the vaccine was safe and well tolerated.

A company statement said, “The currently approved vaccines used as precautionary/booster doses are designed against the ancestral strain of SARS-CoV-2. Although these will increase the antibody titers, their ability to neutralise the circulating Omicron variant of SARS-CoV-2 is limited. Developing antibodies and memory immune responses specific to the Omicron variant would reduce the probability of infection and hospitalisation and prevent future waves of the pandemic. The Made-in-India GEMCOVAC-OM specifically addresses this gap.”

GEMCOVAC-OM is a lyophilised (freeze dried) vaccine, stable at 2- 8 °C.

It is delivered intradermally using a device called Tropis, developed by PharmaJet, US. This is a needle-free device that obviates the disadvantages of using a needle, such as a needle phobia, sharps disposal, and needle-stick injuries, to name a few, said a company statement.

The post
Please, Log in or Register to view URLs content!
appeared first on
Please, Log in or Register to view URLs content!
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock